STING1 and neoplasm: We found that STING agonist combined with B cell depletion effectively delayed tumor growth and significantly prolonged survival without limiting toxicities (STINGa + aCD19/aB220 vs STINGa + IgG, HR=0.38, p=0.02, log-rank test) (Figs. 3E, F and S6A).